Hematologist. Treat and study thrombosis and hemostasis in cancer patients. Passionate #Arsenal⚽️supporter & 🧘🏼♂️.
Joined June 2019
- Tweets 96
- Following 129
- Followers 202
- Likes 245
5 Photos and videos
Avi Leader retweeted
12 Oct 2023
Simple intervention that makes sense! STRATUS #RCT trial led by Dr @DebSiegal and @PHRIresearch in @JAMA_current reported that using small-volume tubes for 🩸 collection⬇️ RBC transfusion in ICU patients. ↔️ in insufficient specimens.
jamanetwork.com/journals/jam…
1
11
40
3,267
Avi Leader retweeted
1 Oct 2023
VTE patients with brain cancer have an increased risk for intracranial bleeding during anticoagulation
Another study by the #RIETEregistry team, leaded by Cecilia Becattini and Michela Giustozzi
20
49
4,171
Avi Leader retweeted
30 Aug 2023
New 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria are out!
Patients need at least 3 points each from the clinical and lab domains (See below) to be classified as having APS. This will be very useful to clinicians :)
acrjournals.onlinelibrary.wi…
@isth
1
55
114
17,758
Avi Leader retweeted
18 Jul 2023
#Match2024 & #FellowMatch
@MSKCancerCenter @MSK_DeptOfMed @TheNRMP @HemOncFellows
I am happy to announce the MSKCC Hematology Focused Fellowship track!
mskcc.org/hcp-education-trai…
17
71
15,723
Avi Leader retweeted
27 Jun 2023
@LeaderAvi presents results from the ABC registry for AC with DOAC or LMWH in brain tumors.
- 🚫diff in rate of spontaneous (not caused by surgery) ICH between DOAC vs LMWH (but numerically ⬇️ with DOAC)
#ISTH2023
4
6
494
Avi Leader retweeted
27 Jun 2023
What is the risk of ICH in patients using DOAC vs LMWH with primary or metastatic brain tumor? @LeaderAvi presents the ABC study at #ISTH2023
1
3
19
2,578
Avi Leader retweeted
26 Jun 2023
🚨Great guidance paper from @AnnaFalanga19 & @LeaderAvi et al. to help with management of these challenging situations.
pubmed.ncbi.nlm.nih.gov/3592…
10
23
4,801
Avi Leader retweeted
26 Jun 2023
LIVE NOW: @LeaderAvi #ISTH2023 SOA Address: Arterial thrombosis is ↑ in cancer & under-treated. Challenges in treatment include ↑ bleeding, drug-drug interactions & ↓ platelets. Cancer-specific #thrombosis management shown ⬇️ in #CoagCapsule. isth.org/23Capsules
7
21
1,801
Avi Leader retweeted
26 Jun 2023
Pts with cancer are at ⬆️ risk of ATE including IS 🧠
Cancer is a known cause of ESUS.
Tx of ESUS in cancer is not well defined.
Pts with cancer and ESUS have a ⬆️ risk of recurrent stroke with DOACs or ASA
Future RCTs are needed (and planned) to guide tx
@LeaderAvi #ISTH2023
1
6
19
1,677
Avi Leader retweeted
26 Jun 2023
Dr. @LeaderAvi providing a great overview of arterial thromboembolism (ATE) in patients with cancer. ATE are often neglected in CAT literature. ATE is common in new diagnosed patient and associates with higher mortality!
#ISTH2023
1
8
30
1,441
Avi Leader retweeted
26 Jun 2023
A Fib is common in patient with cancer. These patients are at higher risk if ATE but also at high risk of bleeding is also high. Good guidance are available to help clinicians #ISTH2023
@LeaderAvi
1
8
26
2,563
Avi Leader retweeted
24 Jun 2023
Dr. @LeaderAvi presented the second phase of the ABC study which reported on the 65 patients with ICH on anticoagulation during the study. Majority of ICH are overt and intramural. VTE is frequent after ICH. No clear association between AC management and VTE post-ICH.
#ISTH2023
1
10
516
Avi Leader retweeted
24 Jun 2023
Severity of ICH was similar for patients on DOACs and LMWH @LeaderAvi #ISTH2023
4
12
776
Avi Leader retweeted
31 May 2023
📣Publication alert: finally published in @TheLancet , the ALIFE2 trial. So thankful to all women who participated and all colleagues who joined the study. LMWH does NOT improve live birth in women with #thrombophilia and #recurrent miscarriage.
thelancet.com/pb-assets/Lanc…
18
114
276
55,618
Avi Leader retweeted
15 May 2023
Patients with cancer-associated #thrombosis and #thrombocytopenia have high risks of recurrent VTE and major bleeding. Future RCTs such as the START trial (NCT05255003) are needed!
authors.elsevier.com/c/1h4w5… in @ThrombosisRese1
@MarcCarrier1 @DellucAurelien
15
54
5,367
20 Apr 2023
Now available:
Podcast🎧🗣️ jacc.org/do/10.1016/podcast-…
Editorial 📄 jacc.org/doi/10.1016/j.jacca…
21 Jan 2023
Pop-based cohort of atrial fib/flutter pts with CHA2DS2-VASc score 0-2 not receiving anticoagulation. Newly-diagnosed cancer associated with 2.7-fold ⬆️ in 12-month ATE risk (vs. no cancer). @JACCJournals sciencedirect.com/science/ar… #cvCoag #AFib #CardioOnc
2
194
Avi Leader retweeted
13 Apr 2023
If cerebral vein thrombosis (#CVT) fails to recanalise after 3-6 months, the risk of CVT recurrence is 8.8x higher. Suggests that anticoagulation length should vary depending on recanalisation status. Free PDF in @RPTHjournal.
tinyurl.com/hzk2f864
3
19
40
4,700
Now in a large population-based cohort - pts w/ ALK #lungcancer at a significantly higher risk for #VTE vs nonALK #nsclc. Awareness is 🗝️! do we need data or start using prphl💊?
academic.oup.com/oncolo/adva…
2
9
21
1,556
Avi Leader retweeted
26 Mar 2023
📢Alert! Women with #superficial vein #thrombosis (SVT) in #pregnancy had a 10.4% risk of having #VTE in that same pregnancy or postpartum period. That is a huge risk justifying treatment of #SVT. @TheLancetHaem Free download until May 13, 2023 authors.elsevier.com/c/1goj-…
2
65
118
28,163
Avi Leader retweeted
7 Feb 2023
Most venous #thrombosis #VTE pts ▶️treated DOACs 💊 In new #JTHiC case-based discussion for DOAC interruption perioperatively in pts receiving VTE anticoagulation. #JTHiC @connors_md @jlberrymd @rushadpatell @jzbos @BIDMC_HOFellows
@MSKcancercenter
bit.ly/3Y5dpID
5
11
2,259